Nevro Corp (NASDAQ:NVRO) CEO Rami Elghandour sold 3,000 shares of the stock in a transaction that occurred on Monday, October 10th. The shares were sold at an average price of $100.00, for a total transaction of $300,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Nevro Corp (NASDAQ:NVRO) traded up 2.15% during trading on Wednesday, hitting $98.49. 516,655 shares of the company were exchanged. Nevro Corp has a 12 month low of $36.51 and a 12 month high of $106.93. The company has a 50-day moving average of $97.64 and a 200-day moving average of $79.50. The company’s market capitalization is $2.81 billion.

Nevro Corp (NASDAQ:NVRO) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.16. The firm earned $55.40 million during the quarter, compared to analyst estimates of $45.11 million. Nevro Corp’s revenue was up 385.5% compared to the same quarter last year. Analysts forecast that Nevro Corp will post ($1.42) EPS for the current year.

Insider Buying and Selling by Quarter for Nevro Corp (NASDAQ:NVRO)

A number of large investors have recently added to or reduced their stakes in the stock. Daiwa Securities Group Inc. bought a new stake in Nevro Corp during the second quarter worth about $545,000. Bank of Montreal Can bought a new stake in Nevro Corp during the second quarter worth about $344,000. American Century Companies Inc. increased its stake in Nevro Corp by 209.1% in the second quarter. American Century Companies Inc. now owns 243,184 shares of the company’s stock worth $17,937,000 after buying an additional 164,505 shares during the last quarter. Essex Investment Management Co. LLC increased its stake in Nevro Corp by 40.9% in the second quarter. Essex Investment Management Co. LLC now owns 12,860 shares of the company’s stock worth $949,000 after buying an additional 3,735 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Nevro Corp by 14.8% in the second quarter. Bank of New York Mellon Corp now owns 156,441 shares of the company’s stock worth $11,539,000 after buying an additional 20,180 shares during the last quarter.

Several analysts have recently weighed in on NVRO shares. Bank of America Corp. started coverage on shares of Nevro Corp in a research note on Monday, August 8th. They issued a “buy” rating and a $100.00 price target for the company. Wells Fargo & Co. started coverage on shares of Nevro Corp in a research note on Tuesday, July 12th. They issued an “outperform” rating for the company. Piper Jaffray Cos. started coverage on shares of Nevro Corp in a research note on Friday, July 22nd. They issued an “overweight” rating and a $98.00 price target for the company. Zacks Investment Research raised shares of Nevro Corp from a “hold” rating to a “buy” rating and set a $110.00 price target for the company in a research note on Wednesday, October 5th. Finally, Morgan Stanley reissued a “buy” rating and issued a $86.00 price target on shares of Nevro Corp in a research note on Wednesday, June 29th. Eleven analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus target price of $104.00.

About Nevro Corp

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.

5 Day Chart for NASDAQ:NVRO

Receive News & Stock Ratings for Nevro Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp and related stocks with our FREE daily email newsletter.